HRP20050744A2 - 4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis - Google Patents

4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis

Info

Publication number
HRP20050744A2
HRP20050744A2 HR20050744A HRP20050744A HRP20050744A2 HR P20050744 A2 HRP20050744 A2 HR P20050744A2 HR 20050744 A HR20050744 A HR 20050744A HR P20050744 A HRP20050744 A HR P20050744A HR P20050744 A2 HRP20050744 A2 HR P20050744A2
Authority
HR
Croatia
Prior art keywords
ylmethoxy
oxazol
cyclohexyloxy
atherosclerosis
phenyl
Prior art date
Application number
HR20050744A
Other languages
English (en)
Croatian (hr)
Inventor
Stapper Christian
Keil Stefanie
Glombik Heiner
Falk Eugen
Goerlitzer Jochen
Gretzke Dirk
Schaefer Hans-Ludwig
Wendler Wolfgang
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of HRP20050744A2 publication Critical patent/HRP20050744A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
HR20050744A 2003-02-27 2004-02-19 4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis HRP20050744A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001586 WO2004076428A1 (de) 2003-02-27 2004-02-19 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (1)

Publication Number Publication Date
HRP20050744A2 true HRP20050744A2 (en) 2006-09-30

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
HR20050744A HRP20050744A2 (en) 2003-02-27 2004-02-19 4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis
HR20050743A HRP20050743A2 (en) 2003-02-27 2004-02-19 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis
HR20050742A HRP20050742A2 (en) 2003-02-27 2004-02-19 3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis

Family Applications After (2)

Application Number Title Priority Date Filing Date
HR20050743A HRP20050743A2 (en) 2003-02-27 2004-02-19 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis
HR20050742A HRP20050742A2 (en) 2003-02-27 2004-02-19 3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis

Country Status (34)

Country Link
US (5) US7259177B2 (pl)
EP (3) EP1599455B1 (pl)
JP (3) JP2006519194A (pl)
KR (3) KR20050105492A (pl)
CN (3) CN100398526C (pl)
AR (3) AR043432A1 (pl)
AT (3) ATE365159T1 (pl)
AU (3) AU2004215673B2 (pl)
BR (3) BRPI0407907A (pl)
CA (3) CA2516620A1 (pl)
CL (2) CL2004000392A1 (pl)
CO (2) CO5690578A2 (pl)
DE (4) DE10308355A1 (pl)
DK (3) DK1599455T3 (pl)
EC (2) ECSP055985A (pl)
ES (3) ES2329366T3 (pl)
HR (3) HRP20050744A2 (pl)
IL (2) IL170316A (pl)
MA (3) MA27737A1 (pl)
MX (3) MXPA05008988A (pl)
NO (3) NO20054408L (pl)
OA (2) OA13034A (pl)
PA (1) PA8596801A1 (pl)
PE (3) PE20040959A1 (pl)
PL (3) PL378130A1 (pl)
PT (3) PT1599452E (pl)
RS (1) RS20050594A (pl)
RU (3) RU2005129995A (pl)
SA (1) SA04250153A (pl)
TN (2) TNSN05206A1 (pl)
TW (3) TW200500349A (pl)
UY (2) UY28210A1 (pl)
WO (3) WO2004076427A1 (pl)
ZA (2) ZA200505768B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039533B4 (de) 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
BRPI0621960A2 (pt) 2006-08-10 2011-12-27 Wood One Co Ltd composiÇço hipoglicÊmica contendo derivado da casca de acÁcia
EP2181087B1 (en) 2007-08-16 2015-10-14 Solvay Sa Process for the preparation of esters of 4-fluorosubstituted 3-oxo-alcanoic acids
CN103435593B (zh) * 2008-02-29 2015-01-28 日产化学工业株式会社 噻吩化合物及其中间体的制造方法
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
KR102640007B1 (ko) 2017-12-13 2024-02-27 캐논 가부시끼가이샤 프로세스 카트리지
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) * 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CZ220498A3 (cs) 1996-01-17 1998-11-11 Novo Nordisk A/S Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DE69723869T2 (de) 1996-12-31 2004-04-22 Dr. Reddy's Laboratories Ltd. Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
EP1000066A1 (en) 1997-07-16 2000-05-17 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
JP4345230B2 (ja) * 1998-03-10 2009-10-14 小野薬品工業株式会社 カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
AU5443499A (en) * 1998-08-27 2000-03-21 Ono Pharmaceutical Co. Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6908926B1 (en) * 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
IL145922A0 (en) 1999-04-28 2002-07-25 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
PT1177176E (pt) * 1999-04-28 2006-08-31 Aventis Pharma Gmbh Derivados de acidos triarilicos como ligandos de receptores ppar.
CA2371271A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
CA2376919C (en) 1999-06-18 2008-11-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
DK1204654T3 (da) 1999-07-29 2003-11-17 Lilly Co Eli Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister
BR0013727A (pt) * 1999-09-01 2002-05-07 Aventis Pharma Gmbh Derivados de sulfonilcarboxamida, processo para sua preparação e seu uso como medicamento
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
ES2215769T3 (es) 1999-12-03 2004-10-16 Astrazeneca Ab Forma cristalina de acido (s)-2-etoxi-3-(4-(2-(4-metanosulfoniloxifenil)etoxi)fenil)propanoico.
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
AU2001254763A1 (en) 2000-03-31 2001-10-08 Prosidion Limited Method for the improvement of islet signaling in diabetes mellitus and for its prevention
HUP0300475A3 (en) 2000-04-25 2004-10-28 Kyorin Seiyaku Kk Novel stable crystal of thiazolidinedione derivative and process for producing the same
PT1277736E (pt) 2000-04-28 2007-10-12 Asahi Kasei Pharma Corp Novos compostos bicíclicos
JP2004507456A (ja) 2000-05-11 2004-03-11 ブリストル−マイヤーズ　スクイブ　カンパニー 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
EP1294682B1 (de) * 2000-06-09 2004-04-28 Aventis Pharma Deutschland GmbH Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
DE60129712T2 (de) 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
CA2418104A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
AU2002222573A1 (en) 2000-12-05 2002-06-18 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
HUP0401081A3 (en) 2000-12-21 2010-06-28 Sanofi Aventis Deutschland Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and their use
NZ526687A (en) * 2000-12-25 2004-08-27 Ono Pharmaceutical Co Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient
EP1360172A1 (en) * 2001-02-15 2003-11-12 Pfizer Products Inc. Ppar agonists
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
EA200400011A1 (ru) * 2001-06-07 2004-06-24 Эли Лилли Энд Компани Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar)
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003004458A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab New compounds
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
JP4436129B2 (ja) 2001-08-31 2010-03-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ジアリールシクロアルキル誘導体、その製造法及びｐｐａｒ−活性剤としてのその使用
WO2003066581A1 (en) 2002-02-05 2003-08-14 Eli Lilly And Company Urea linker derivatives for use as ppar modulators
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
AU2003259131A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
CA2516620A1 (en) 2004-09-10
ATE435217T1 (de) 2009-07-15
AR043427A1 (es) 2005-07-27
CO5690580A2 (es) 2006-10-31
AU2004215672A1 (en) 2004-09-10
WO2004076426A1 (de) 2004-09-10
NO20054408D0 (no) 2005-09-22
OA13034A (en) 2006-11-10
EP1599453A1 (de) 2005-11-30
JP2006519194A (ja) 2006-08-24
MXPA05008951A (es) 2005-11-04
PL378130A1 (pl) 2006-03-06
ATE430738T1 (de) 2009-05-15
CA2517381A1 (en) 2004-09-10
DE10308355A1 (de) 2004-12-23
DK1599452T3 (da) 2007-10-01
MXPA05008988A (es) 2005-10-18
OA13035A (en) 2006-11-10
MA27736A1 (fr) 2006-02-01
HRP20050742A2 (en) 2006-09-30
NO20054398L (no) 2005-11-02
NO20054396D0 (no) 2005-09-22
RU2005129995A (ru) 2006-01-27
SA04250153A (ar) 2005-12-03
DK1599455T3 (da) 2009-11-09
US7259177B2 (en) 2007-08-21
TNSN05206A1 (en) 2007-06-11
AU2004215673B2 (en) 2009-10-01
US20050215596A1 (en) 2005-09-29
ECSP055986A (es) 2006-01-16
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
RS20050594A (sr) 2007-12-31
AU2004215677A1 (en) 2004-09-10
US20040209920A1 (en) 2004-10-21
ZA200505768B (en) 2005-11-23
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
MA27742A1 (fr) 2006-02-01
US7365084B2 (en) 2008-04-29
CN1753881A (zh) 2006-03-29
KR20050106461A (ko) 2005-11-09
CN100439347C (zh) 2008-12-03
NO20054396L (no) 2005-11-11
AU2004215673A1 (en) 2004-09-10
ATE365159T1 (de) 2007-07-15
BRPI0407907A (pt) 2006-02-14
PT1599452E (pt) 2007-09-12
PE20050293A1 (es) 2005-05-24
AU2004215677B2 (en) 2010-01-07
US20080015238A1 (en) 2008-01-17
PT1599455E (pt) 2009-09-29
BRPI0407814A (pt) 2006-02-14
RU2005130002A (ru) 2006-01-27
US7335671B2 (en) 2008-02-26
PT1599453E (pt) 2009-07-14
KR20050105492A (ko) 2005-11-04
MA27737A1 (fr) 2006-02-01
IL170314A (en) 2010-11-30
MXPA05008995A (es) 2005-10-18
AU2004215672B2 (en) 2010-01-07
KR20050106462A (ko) 2005-11-09
TNSN05204A1 (en) 2007-06-11
US20050101637A1 (en) 2005-05-12
WO2004076428A1 (de) 2004-09-10
NO20054398D0 (no) 2005-09-22
CN1756748A (zh) 2006-04-05
PL378437A1 (pl) 2006-04-03
EP1599455B1 (de) 2009-07-01
EP1599452A1 (de) 2005-11-30
WO2004076427A1 (de) 2004-09-10
US20080167354A1 (en) 2008-07-10
CO5690578A2 (es) 2006-10-31
DK1599453T3 (da) 2009-08-24
AR043432A1 (es) 2005-07-27
CL2004000392A1 (es) 2005-04-22
UY28210A1 (es) 2004-09-30
PE20040959A1 (es) 2005-01-17
EP1599455A1 (de) 2005-11-30
TW200508210A (en) 2005-03-01
EP1599453B1 (de) 2009-05-06
DE502004004139D1 (de) 2007-08-02
US7872034B2 (en) 2011-01-18
CN100398526C (zh) 2008-07-02
PL377735A1 (pl) 2006-02-20
UY28209A1 (es) 2004-09-30
TW200500349A (en) 2005-01-01
CL2004000391A1 (es) 2005-01-07
CA2517386A1 (en) 2004-09-10
ES2287700T3 (es) 2007-12-16
CN1753879A (zh) 2006-03-29
EP1599452B1 (de) 2007-06-20
RU2005129992A (ru) 2006-02-10
JP2006519199A (ja) 2006-08-24
ES2329366T3 (es) 2009-11-25
ECSP055985A (es) 2006-01-16
AR043433A1 (es) 2005-07-27
ZA200505765B (en) 2006-05-31
DE502004009453D1 (de) 2009-06-18
TW200510352A (en) 2005-03-16
JP2006519193A (ja) 2006-08-24
PE20050292A1 (es) 2005-05-24
CN100439345C (zh) 2008-12-03
BRPI0407758A (pt) 2006-02-14
ES2326418T3 (es) 2009-10-09
DE502004009690D1 (de) 2009-08-13

Similar Documents

Publication Publication Date Title
HRP20050742A2 (en) 3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis
HRP20050531B1 (hr) Novi aromatski derivati fluorglikozida, lijek koji sadrži te spojeve i njihova upotreba
WO2006099943A8 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
MXPA05012840A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
MA27134A1 (fr) Derives diarylcycloalkyle, leur procede de preparation et leur utilisation en tant qu'activateurs des ppar
DE602007006010D1 (de) Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
ATE411280T1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
MX336966B (es) Novedosos derivados y su uso en el tratamiento de transtornos neurologicos.
NO20055892L (no) Karboksylsyrederivater
TW200505862A (en) 2-amino-pyridine derivatives useful for the treatment of diseases
WO2005080313A3 (en) Sulfonamide derivatives for the treatment of diseases
JO2449B1 (en) Thiosol derivatives - benziazothiazole dioxide, methods of preparation and use.
TW200505865A (en) Compounds useful for the treatment of diseases
ATE411296T1 (de) Imidazolinderivate mit cb1-antagonistischer wirkung
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
HRP20050308A2 (en) Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists
HRP20050739A2 (en) Cycloalkyl-substituted alkanoic acid derivatives, methods for the production thereof, and use thereof as a medicament
ATE370949T1 (de) Heterocyclisch substituierte 7-amino-4-chinolon-3-carbonsäure-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2005097762A3 (en) 1,3,4-oxadiazol-2-ones as ppar delta modulators
DE50010285D1 (de) Verwendung von polycyclischen 2-amino-thiazol systemen zur herstellung von medikamenten zur behandlung von fettstoffwechselstörungen, obesitas und typ ii diabetes
CA2654354C (en) Amino derivatives of b-homoandrostanes and b-heteroandrostanes
HRP20050779A2 (en) Supstituted benzoylureidopyridyl-piperidine and pyrrolidine carboxylic acid derivatives, method for the production thereof and the use thereof
NO20063859L (no) Cykloalkylsubstituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og anvendelse derav som medikamenter

Legal Events

Date Code Title Description
ODRP Renewal fee for the maintenance of a patent

Payment date: 20051229

Year of fee payment: 3

A1OB Publication of a patent application
OBST Application withdrawn